Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the ...

Agenus Inc. , a leader in immuno-oncology innovation, today announced that France's National Agency for Medicines and Health Products Safety (ANSM) has approved an updated national treatment protocol ...

Eisai And Nuvation Bio Enter Into Exclusive Licensing Agreement For Taletrectinib In Europe And Additional Countries Outside The U.S., China And Japan. Eisai and Nuvation Bio Enter into Exclusive ...

Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the ...

Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range ...

EDM Resources Inc. is pleased to provide a summary of its key accomplishments during 2025 and to outline its planned ...